Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
National Australia Bank earnings: Standing ground in business lending, but no earnings growth
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,950.18 | 124.05 | -1.54% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 323.90 | -0.68% |
| FTSE 100 | 9,646.00 | 89.78 | -0.92% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 23,004.54 | 495.26 | -2.11% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |